CD79B

CD79B Molekülinformation

Englischer Name	B-cell antigen receptor complex-associated protein beta chain	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	9	Target-Alias	B-Cell Antigen Receptor Complex-Associated Protein Beta Chain，B29，Immunoglobulin-associated B29 protein，Ig-beta，B-cell-specific glycoprotein B29，CD79B，CD79b Molecule，CD79b Molecule， Immunoglobulin-Associated Beta，IGB，CD79B Antigen (Immunoglobulin-Associated Beta)，CD79b Antigen，AGM6
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	B-cell antigen receptor complex-associated protein beta chain
Target-Alias	B-Cell Antigen Receptor Complex-Associated Protein Beta Chain，B29，Immunoglobulin-associated B29 protein，Ig-beta，B-cell-specific glycoprotein B29，CD79B，CD79b Molecule，CD79b Molecule， Immunoglobulin-Associated Beta，IGB，CD79B Antigen (Immunoglobulin-Associated Beta)，CD79b Antigen，AGM6
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	9
Höchste Forschungs- und Entwicklungsphase	Approved

CD79B Produktliste

Attribut
Protein (9)Cell (1)
Produktbibliothek
Online (10)
Spezies
Human (5)Mouse (3)Cynomolgus (2)
Etikett
Fc Tag (2)His Tag (4)His Tag & Avi Tag (3)- (1)
Marker
Unconjugated (5)Biotin-labeled (3)PE Labeled (1)- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT CDB-H5259	Human	HEK293	Human CD79B Protein, Fc Tag, low endotoxin	In den Warenkorb legen
HOT CDB-H52H3	Human	HEK293	Human CD79B Protein, His Tag, low endotoxin (MALS verified)	In den Warenkorb legen
HOT CDB-H82E3	Human	HEK293	Biotinylated Human CD79B Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
HOT CDB-HP2H6	Human	HEK293	PE-Labeled Human CD79B Protein, His Tag (Site-specific conjugation)	In den Warenkorb legen
SCCHO-ATP171	Human	CHO	CHO/Human CD79B Stable Cell Line	In den Warenkorb legen
CDB-M5253	Mouse	HEK293	Mouse CD79B Protein, Fc Tag (MALS verified)	In den Warenkorb legen
CDB-M52H4	Mouse	HEK293	Mouse CD79B Protein, His Tag, low endotoxin (MALS verified)	In den Warenkorb legen
CDB-M82E3	Mouse	HEK293	Biotinylated Mouse CD79B Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
CDB-C52H3	Cynomolgus	HEK293	Cynomolgus CD79B Protein, His Tag (MALS verified)	In den Warenkorb legen
CDB-C82E5	Cynomolgus	HEK293	Biotinylated Cynomolgus CD79B Protein, His,Avitag™	In den Warenkorb legen

Gesamtmenge10

CD79B Molekülhintergrund

B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

CD79B Molekülalias

CD79b,B29,IGB,Ig-beta

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
SHR-A1912	SHR-A1912	Phase 3 Clinical	Shanghai Hengrui Pharmaceutical Co Ltd	Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse	Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)	bi-4SCAR CD19/79b	Phase 2 Clinical	Shenzhen Geno-Immune Medical Institute	Leukemia, B-Cell; Lymphoma, B-Cell	Details
TolDCB29		Phase 2 Clinical	Umc Utrecht	Arthritis, Rheumatoid	Details
JNJ-95566692	JNJ-95566692	Phase 1 Clinical	Janssen Research & Development Llc	Lymphoma, Non-Hodgkin	Details
LTZ-301	LTZ-301	Phase 1 Clinical	LTZ Therapeutics Inc	Autoimmune Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin	Details
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital)		Phase 1 Clinical	Massachusetts General Hospital	Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Primary mediastinal B cell lymphoma	Details
Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy（MD Anderson Cancer Center）	JV-213	Phase 1 Clinical	The University Of Texas MD Anderson Cancer Center	Lymphoma; Lymphoma, B-Cell	Details
NBT-508		Phase 1 Clinical	Newbio Therapeutics Inc	Lymphoma, B-Cell; Lymphoma, Non-Hodgkin	Details
CD79b CAR-T cell therapy (Yake Biotechnology)		Phase 1 Clinical	Shanghai YaKe Biotechnology Co Ltd, Zhejiang University	Leukemia, Biphenotypic, Acute; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Polatuzumab vedotin	RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077	Approved	Genentech Inc, Seagen Inc	Polivy, 优罗华	United States	Lymphoma, Large B-Cell, Diffuse	Genentech Inc	2019-06-10	Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin	Details